Most material SEC filings — October 23, 2026

MarketAxess reported Q3 2026 revenues of $210.4M (flat commissions, +6% services), with diluted EPS of $1.53 GAAP ($1.86 ex-notable items). The company announced a pending merger with Intercontinental Exchange Inc. at $167.00 cash per share, approved by DOJ/FTC on October 21, 2026. Merger completion remains subject to stockholder approval and other conditions. The company suspended earnings calls, guidance, and monthly volume press releases pending deal closure. Key operational metrics: block trading ADV +21%, portfolio trading ADV +37%, but operating margin compressed 560 bps to 35.4% due to $13.1M in merger-related expenses.

Zymeworks entered into an exclusive global license and collaboration agreement with Roche for ZW209, a trispecific T cell engager targeting DLL3. Zymeworks receives $55 million upfront, $40 million upon Phase 1b initiation, and up to $718 million in development/commercial/sales milestones, plus tiered high-single-digit to mid-teen royalties on global net sales. Roche funds Phase 1a trial and holds exclusive global development and commercialization rights; deal closes subject to HSR Act clearance.

Tango Therapeutics announced Phase 1/2 data (cutoff August 20, 2026) for vopimetostat plus daraxonrasib in 22 efficacy-evaluable patients with 2L/3L MTAP-deleted, RAS-mutant pancreatic cancer: 82% objective response rate, median PFS not yet reached, 88% 9-month PFS rate, 100% disease control rate, and generally favorable tolerability (no Grade 4-5 toxicities at dose level 1, 20% dose reduction rate). Tango plans to initiate a global Phase 3 randomized trial in 1H 2027 comparing vopimetostat 200 mg + daraxonrasib 100 mg daily vs. standard-of-care chemotherapy in front-line MTAP-deleted PDAC patients (n=484, dual primary endpoints: ORR and PFS); the company also intends to explore potential 2L approval and expansion into MTAP wild-type tumors.

UY Scuti Acquisition Corp. issued two promissory notes dated October 22, 2026: (1) $900,000 to Isdera HK Limited (representing two prior deposits of $450,000 each on June 30 and September 30, 2026 into the trust account), and (2) up to $200,000 drawdown facility to Xinghui Automotive Technology (Hainan) Co., Ltd. for transaction costs. Both notes are convertible into units at $10.00 per unit (each unit = 1 share + 1/5 warrant), with maturity on business combination closing. No interest accrues. Payees waive claims against the IPO trust account. Conversion is prohibited if the holder becomes a PubCo subsidiary at closing; in such cases, settlement occurs via cash, intercompany set-off, or other mechanisms.